Microvast Holdings announces departure of chief financial officer
Investing.com - Stifel maintained its Buy rating and $115.00 price target on Glaukos Corporation (NYSE:GKOS), currently trading at $101.42, following analyst attendance at an iDose webinar hosted by the highest-volume iDose practice in the United States. The $5.8 billion market cap company maintains a strong "Buy" consensus among analysts, with targets ranging from $72 to $165.
The research firm reported increased confidence that iDose’s favorable financial profile for medical practices will likely support adoption as clinics become more comfortable with reimbursement processes. This assessment came after participation in another iDose webinar led by a Glaukos Senior Reimbursement Liaison. According to InvestingPro data, Glaukos demonstrates solid financial health with a "GOOD" overall score, showing impressive revenue growth of nearly 24% over the last twelve months.
Stifel noted that early real-world iDose safety data from the FDA’s Adverse Events Reporting System appears "encouragingly clean" and aligns with phase 3 study results, reinforcing confidence in positive outcomes and the product’s value proposition.
The firm acknowledged that while Medicare Administrative Contractors (MACs) weren’t fully prepared for iDose’s reimbursement nuances, which are new to the glaucoma ecosystem, progress on reimbursement is considered inevitable, particularly regarding the physician fee.
Stifel indicated these positive takeaways support its long-term optimistic view on iDose, though it maintains a more cautious near-term stance on both iDose and Glaukos that will be reassessed following upcoming quarterly survey checks. For deeper insights into Glaukos’s valuation and growth prospects, InvestingPro subscribers can access 7 additional ProTips and a comprehensive Pro Research Report, transforming complex financial data into actionable intelligence.
In other recent news, Glaukos Corporation announced that it has received European Union Medical (TASE:BLWV) Device Regulation certification for several of its micro-invasive glaucoma surgery devices, including the iStent infinite and iStent inject W. This certification marks a significant milestone for the company as it plans to commence commercial launch activities in Europe in the coming months. Meanwhile, Stifel analysts have maintained a Buy rating for Glaukos, setting a price target of $115, citing a gradual sales ramp for the iDose product. Stephens analysts have also adjusted their price target for Glaukos to $115 from $140, maintaining an Overweight rating despite challenges in the U.S. glaucoma market. The company’s first-quarter results exceeded consensus estimates, driven by strong international glaucoma sales, though domestic sales faced hurdles due to Medicare coverage issues. Needham analysts also revised their price target to $115 from $176, maintaining a Buy rating while noting an increase in projected contributions from the iDose product. Additionally, Glaukos disclosed the voting results from its annual stockholders’ meeting, where all proposals, including director elections and the ratification of Ernst & Young LLP as the accounting firm, were approved. Investors are closely watching for the anticipated FDA decision on iDose re-treatment by the end of 2025, which could significantly impact the company’s market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.